[Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice].

In recent years, the relationship of hyperuricemia and gout with a high risk of cardiovascular disease has been widely discussed. Therefore, it is important to systematically examine patients in order to diagnose comorbidities, among which cardiovascular disease and its complications occupy a leading place and consider mandatory treatment of patients with hyperuricemia and gout with high cardiovascular risk with lowering drugs, which fully reflects the provisions of the latest European recommendations for the management and treatment of patients with gout.

• Publication year

  2019

• Venue

  Терапевтический архив

• Publication date

  2019-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.26442/00403660.2019.12.000173PMID 32598593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.

  2018cited by this paper
• Cardiac and renal protective effects of urate-lowering therapy

  2018cited by this paper
• Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.

  2017cited by this paper
• Association Between Gout and Aortic Stenosis.

  2017cited by this paper
• Gout: An old disease in new perspective – A review

  2017cited by this paper
• Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study

  2017cited by this paper
• Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options

  2017cited by this paper
• Gout: Risk of premature death in gout unchanged for years

  2017cited by this paper
• Uric acid and essential hypertension: the endothelial connection.

  2016cited by this paper
• Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.

  2016cited by this paper
• A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis.

  2016cited by this paper
• Impact of gout on the risk of atrial fibrillation.

  2016cited by this paper
• Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health.

  2016cited by this paper
• Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study.

  2016cited by this paper
• Risk of acute gout among active smokers: data from nationwide inpatient sample

  2016cited by this paper
• Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease.

  2016cited by this paper
• Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study

  2016cited by this paper
• Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta‐analysis

  2016cited by this paper
• New medications in development for the treatment of hyperuricemia of gout

  2015cited by this paper
• Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.

  2015cited by this paper
• Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s).

  2015cited by this paper
• Serum uric acid and the risk of cardiovascular and renal disease.

  2015cited by this paper
• Uric Acid and Cardiovascular Events: A Mendelian Randomization Study.

  2015cited by this paper
• Gout and Risk of Myocardial Infarction: A Systematic Review and Meta-Analysis of Cohort Studies

  2015cited by this paper
• Cigarette Smoking and the Risk of Incident Gout in a Prospective Cohort Study

  2015cited by this paper
• Allopurinol use and risk of non-fatal acute myocardial infarction

  2015cited by this paper
• Relation of Lipid Content of Coronary Plaque to Level of Serum Uric Acid.

  2015cited by this paper
• Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort.

  2015cited by this paper
• Gout and the heart.

  2014cited by this paper
• Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study

  2014cited by this paper
• Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink

  2014cited by this paper
• Attenuating the mortality risk of high serum uric acid: the role of physical activity underused

  2014cited by this paper
• Correlations between serum uric acid and coronary atherosclerosis before and during statin therapy

  2014cited by this paper
• Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment.

  2014cited by this paper
• Impact of allopurinol on risk of myocardial infarction

  2014cited by this paper
• Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9

  2014cited by this paper
• Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study

  2014cited by this paper
• A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study

  2014cited by this paper
• Emerging therapies for gout.

  2014cited by this paper
• 2016 updated EULAR evidence-based recommendations for the management of gout

  2014cited by this paper
• Comorbidities in patients with gout prior to and following diagnosis: case-control study

  2014cited by this paper
• Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts

  2013cited by this paper
• Uric acid as a danger signal in gout and its comorbidities

  2013cited by this paper
• Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis

  2013cited by this paper
• Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies.

  2013cited by this paper
• Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout

  2013cited by this paper
• Low-dose colchicine for secondary prevention of cardiovascular disease.

  2013cited by this paper
• Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients.

  2013cited by this paper
• Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study

  2013cited by this paper
• Low-dose aspirin use and recurrent gout attacks

  2013cited by this paper
• Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality.

  2013cited by this paper
• Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.

  2012cited by this paper
• Gout and the risk for incident heart failure and systolic dysfunction

  2012cited by this paper
• Serum Uric Acid and Adiposity: Deciphering Causality Using a Bidirectional Mendelian Randomization Approach

  2012cited by this paper
• Genotype-based changes in serum uric acid affect blood pressure.

  2012cited by this paper
• Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.

  2012cited by this paper
• Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.

  2012cited by this paper
• Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study

  2012cited by this paper
• Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

  2012cited by this paper
• Gout and hyperuricemia in young people

  2011cited by this paper
• Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

  2011cited by this paper
• Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

  2011cited by this paper
• Frequency and risk factors of gout flares in a large population-based cohort of incident gout.

  2011cited by this paper
• Allopurinol as a Cardiovascular Drug

  2011cited by this paper
• Prevalence of contraindications and prescription of pharmacologic therapies for gout.

  2011cited by this paper
• Uric acid transport and disease.

  2010cited by this paper
• Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors

  2010cited by this paper
• Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study

  2010cited by this paper
• Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response

  2010cited by this paper
• Bayesian methods for instrumental variable analysis with genetic instruments (‘Mendelian randomization’): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome

  2010cited by this paper
• High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

  2010cited by this paper
• Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial

  2009cited by this paper
• Hyperuricemia and risk of stroke: a systematic review and meta-analysis.

  2009cited by this paper
• Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.

  2008cited by this paper
• SLC2A9 influences uric acid concentrations with pronounced sex-specific effects

  2008cited by this paper
• Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

  2008cited by this paper
• Uric acid and cardiovascular risk.

  2008cited by this paper
• Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease

  2007cited by this paper
• Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey.

  2007cited by this paper
• Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials.

  2006cited by this paper
• Gout and the risk of acute myocardial infarction.

  2006cited by this paper
• Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

  2005cited by this paper
• HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

  2005cited by this paper
• Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

  2003cited by this paper
• Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

  2003cited by this paper
• Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism

  2001cited by this paper
• The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study.

  2000cited by this paper
• Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study

  1999cited by this paper
• Plasma uric acid and spironolactone response in healthy subjects.

  1977cited by this paper
• The pathogenesis of podagra.

  1977cited by this paper
• BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.

  1963cited by this paper
• Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

  1959cited by this paper

• Uric acid as one of the markers of polymorbidity in patients with coronary heart disease

  2022cites this paper
• Recent Bibliography, 2018–2021 (With Selected Academic Research)

  2022cites this paper
• Detection and Treatment of Hyperuricemia in Clinical Practice (According to the PROFILE Outpatient Registry)

  2022cites this paper
• Hypertension and asymptomatic hyperuricemia: algorithm of diagnostics and management (literature review)

  2022cites this paper
• Significance of asymptomatic hyperuricemia in ankylosing spondylitis

  2021cites this paper